Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation

被引:0
|
作者
Dewaraja, YK
Wilderman, SJ
Ljungberg, M
Koral, KF
Zasadny, K
Kaminiski, MS
机构
[1] Univ Michigan, Med Ctr, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA
[2] Lund Univ, Dept Med Radiat Phys, S-22100 Lund, Sweden
[3] Pfizer Global Res & Dev, Ann Arbor, MI USA
[4] Univ Michigan, Med Ctr, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA
关键词
3-dimensional dosimetry; radioimmunotherapy; SPECT; Monte Carlo dosimetry; I-131;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
I-131 radionuclide therapy studies have not shown a strong relationship between tumor absorbed dose and response, possibly due to inaccuracies in activity quantification and dose estimation. The goal of this work was to establish the accuracy of I-131 activity quantification and absorbed dose estimation when patient-specific, 3-dimensional (3D) methods are used for SPECT reconstruction and for absorbed dose calculation. Methods: Clinically realistic voxel-phantom simulations were used in the evaluation of activity quantification and dosimetry. SPECT reconstruction was performed using an ordered-subsets expectation maximization (OSEM) algorithm with compensation for scatter, attenuation, and 3D detector response. Based on the SPECT image and a patient-specific density map derived from CT, 3D dosimetry was performed using a newly implemented Monte Carlo code. Dosimetry was evaluated by comparing mean absorbed dose estimates calculated directly from the defined phantom activity map with those calculated from the SPECT image of the phantom. Finally, the 3D methods were applied to a radioimmunotherapy patient, and the mean tumor absorbed dose from the new calculation was compared with that from conventional dosimetry obtained from conjugate-view imaging. Results: Overall, the accuracy of the SPECT-based absorbed dose estimates in the phantom was > 12% for targets down to 16 mL and up to 35% for the smallest 7-mL tumor. To improve accuracy in the smallest tumor, more OSEM iterations may be needed. The relative SD from multiple realizations was < 3% for all targets except for the smallest tumor. For the patient, the mean tumor absorbed dose estimate from the new Monte Carlo calculation was 7% higher than that from conventional dosimetry. Conclusion: For target sizes down to 16 mL, highly accurate and precise dosimetry can be obtained with 3D methods for SPECT reconstruction and absorbed dose estimation. In the future, these methods can be applied to patients to potentially establish correlations between tumor regression and the absorbed dose statistics from 3D dosimetry.
引用
收藏
页码:840 / 849
页数:10
相关论文
共 33 条
  • [21] Dosimetry of regressing tumors in 131I internal emitter therapy using patient data from multiple, integrated CT-SPECT imagesi
    Wilderman, Scott J.
    Dewaraja, Yuni K.
    2007 IEEE NUCLEAR SCIENCE SYMPOSIUM CONFERENCE RECORD, VOLS 1-11, 2007, : 3660 - 3664
  • [22] Activity quantification combining conjugate-view planar scintigraphies and SPECT/CT data for patient-specific 3-D dosimetry in radionuclide therapy
    Yannick Berker
    Andreas Goedicke
    Gerrit J. Kemerink
    Til Aach
    Bernd Schweizer
    European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 2173 - 2185
  • [23] Activity quantification combining conjugate-view planar scintigraphies and SPECT/CT data for patient-specific 3-D dosimetry in radionuclide therapy
    Berker, Yannick
    Goedicke, Andreas
    Kemerink, Gerrit J.
    Aach, Til
    Schweizer, Bernd
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (12) : 2173 - 2185
  • [24] Methodology to Incorporate the BED and EUD in PatientSpecific 3-Dimensional Dosimetry for Non-Hodgkin's Lymphoma Patients Targeted with 131I Tositumomab Therapy
    Amro, H.
    Wilderman, S.
    Dewaraja, Y.
    Roberson, P.
    MEDICAL PHYSICS, 2009, 36 (06)
  • [25] Patient-specific simulation for tracheobronchial reconstruction procedures using 3-dimensional operable models: A proof-of-concept study
    Hashimoto, Kohei
    Omura, Kenshiro
    Iwamoto, Naoya
    Ichinose, Junji
    Matsuura, Yosuke
    Nakao, Masayuki
    Mun, Mingyon
    JTCVS TECHNIQUES, 2022, 14 : 138 - 140
  • [26] Absorbed dose estimation of thyroid residues, salivary glands and distal metastases after 131I therapy using SPECT/CT with scatter, dead time and partial volume correction
    Abuqbeitah, M.
    Demir, M.
    Sager, S.
    Yeyin, N.
    Sonmezoglu, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S317 - S318
  • [27] 131I-Tositumomab Radioimmunotherapy: Initial Tumor Dose-Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling
    Dewaraja, Yuni K.
    Schipper, Matthew J.
    Roberson, Peter L.
    Wilderman, Scott J.
    Amro, Hanan
    Regan, Denise D.
    Koral, Kenneth F.
    Kaminski, Mark S.
    Avram, Anca M.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (07) : 1155 - 1162
  • [28] PREDICTING OUTCOMES FOLLOWING THERAPY FOR GLIOBLASTOMA USING RESPONSE METRICS FROM PATIENT-SPECIFIC 3-DIMENSIONAL TUMOR MODELS
    Neal, Maxwell L.
    Rockne, Russell
    Trister, Andrew D.
    Swanson, Kristin R.
    NEURO-ONCOLOGY, 2011, 13 : 83 - 83
  • [29] Tumor dose-response in I-131 radioimmunotherapy using measures from 3-dimensional calculation including radiobiologic modeling
    Dewaraja, Yuni
    Schipper, Matthew
    Roberson, Peter
    Wilderman, Scott
    Regan, Denise
    Amro, Hanan
    Koral, Kenneth
    Kaminski, Mark
    Avram, Anca
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [30] Characterizing Bone Tunnel Placement in Medial Ulnar Collateral Ligament Reconstruction Using Patient-Specific 3-Dimensional Computed Tomography Modeling
    Byram, Ian R.
    Khanna, Krishn
    Gardner, Thomas R.
    Ahmad, Christopher S.
    AMERICAN JOURNAL OF SPORTS MEDICINE, 2013, 41 (04): : 894 - 902